Astria shareholders approve BioCryst acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Astria Stockholders Vote to Approve Acquisition by BioCryst
January 21, 2026 4:00 PM ESTBOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astrias stockholders held on January 21, 2026, Astrias stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the Merger).
The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.
About Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company, whose mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Astria's lead program, navenibart (STAR-0215), is a monoclonal... More
